Heidelberg Pharma Amends Royalty Agreement with HealthCare Royalty and Soleus Capital Joins

Heidelberg Pharma AG has announced an amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and welcomed Soleus Capital as a new participant. The amendment involves partially monetizing Heidelberg Pharma’s future royalties from Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px.

Heidelberg Pharma is set to receive a USD 20 million upfront payment from Soleus Capital, conditional on certain closing conditions. An additional USD 25 million will be provided by Soleus Capital once the FDA approves TLX250-Px. Payments from HCRx remain unchanged. These developments aim to secure Heidelberg Pharma’s finances until mid-2027.